Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors

A method of treating cancer in a subject in need of such treatment, the method comprising administering an antibody drug conjugate (ADC) and a Bcl-2 inhibitor, wherein the ADC comprises an antibody conjugated to a PBD cytotoxic agent, wherein the Bcl-2 inhibitor is selected from the group consisting of ABT-199 and ABT-263, and wherein the antibody is selected from the group consisting of:

• a) an anti-CD33 antibody comprising the light chain variable region of SEQ ID NO:
• 1 and the heavy chain variable region of SEQ ID NO:
• 2;
• and
• b) and anti-CD19 antibody comprising the light chain variable region of SEQ ID NO:
• 10 and the heavy chain variable region of SEQ ID NO:
• 11.